MERTK

Across TCGA pan-cancer cohorts, MERTK mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MERTK data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MERTK mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MERTK expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where MERTK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.198	0.887	.024	16	view →
PDAC	DFS	Tertile	All	0.832	0.330	.018	7	view →
LSCC	DFS	Tertile	III,IV	0.894	0.396	.017	5	view →
LUAD	DFS	Quartile	II,III,IV	1.000	0.351	.032	4	view →
GBM	DFS	Median	All	0.274	0.467	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MERTK–CCRCC (DFS)

Open the CCRCC breakdown →